Conmed Corp
NYSE:CNMD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/OCF
Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.
Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.
Valuation Scenarios
If EV/OCF returns to its 3-Year Average (18), the stock would be worth $59 (54% upside from current price).
| Scenario | EV/OCF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 11.7 | $38.34 |
0%
|
| 3-Year Average | 18 | $59 |
+54%
|
| 5-Year Average | 41.5 | $136.29 |
+255%
|
| Industry Average | 18.7 | $61.3 |
+60%
|
| Country Average | 16.7 | $54.75 |
+43%
|
Forward EV/OCF
Today’s price vs future operating cash flow
Peer Comparison
| Market Cap | EV/OCF | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Conmed Corp
NYSE:CNMD
|
1.2B USD | 11.7 | 25.6 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
171.2B USD | 54.5 | 60 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
158.3B USD | 16.6 | 25.2 | |
| US |
|
Stryker Corp
NYSE:SYK
|
125.3B USD | 27 | 38.6 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
106.9B USD | 17.4 | 23.2 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
92B USD | 22.3 | 25.8 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
40B EUR | 15.6 | 18.9 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
48.9B USD | 28.4 | 44.6 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
45.1B USD | 38.5 | 42.6 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
43.3B USD | 17.5 | 24.7 | |
| US |
|
Resmed Inc
NYSE:RMD
|
32B USD | 16.2 | 21.6 |
Market Distribution
| Min | 0 |
| 30th Percentile | 11.7 |
| Median | 16.7 |
| 70th Percentile | 23.6 |
| Max | 3 178 983.5 |
Other Multiples
Conmed Corp
Glance View
Conmed Corporation, founded in the small city of Utica, New York, has carved a niche for itself in the competitive world of medical technology. The company, which began its journey in the mid-1970s, has evolved into a global player by specializing in a variety of surgical and patient care products. At its core, Conmed thrives on its deep expertise in the design and manufacturing of surgical instruments used predominantly in minimally invasive procedures. These include sophisticated medical devices for orthopedic, laparoscopic, robotic, and general surgeries. Conmed’s strategic focus has always been on innovation, driven by a commitment to enhance the surgeon's ability to provide superior patient care, which is evident in their continuous research and development efforts aimed at creating more efficient and effective tools for medical professionals. The revenue streams for Conmed are as diversified as their product offerings. By selling advanced surgical equipment and medical products to hospitals, surgical centers, and outpatient facilities worldwide, Conmed positions itself as a critical supplier in the healthcare industry. A significant portion of their income is derived from the repeat sales of disposable items and replacement parts required for these high-tech devices. This creates a continuous cycle of revenue through both initial capital sales and recurring sales of consumables, quintessential for sustaining robust financial stability. Furthermore, the company's growth strategy has been marked by strategic acquisitions, allowing it to broaden its array of products and enter new markets, thereby ensuring its continued prominence and adaptability in the ever-evolving landscape of healthcare technology.